<DOC>
	<DOC>NCT01210404</DOC>
	<brief_summary>Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.</brief_summary>
	<brief_title>Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Males or females, without evidence of infection with HIV,HBV or HCV, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start. Evidence of chronic diseases including HIV, HBV or HCV. Evidence of acute or chronic liver disease. Treatment with prescription or nonprescription drugs other than methadone within 7 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Drug interaction with methadone.</keyword>
</DOC>